Form 4: United Therapeutics Director Sells Shares Under 10b5-1 Plan

United Therapeutics Corp. Director Nilda Mesa reported the sale of 187 common shares under a pre-arranged trading plan.

Summary

• Nilda Mesa, a Director of United Therapeutics Corp. (UTHR), sold 187 shares of common stock.
• The transaction occurred on December 9, 2025, at a price of $481.6301 per share.
• Following this sale, Mesa beneficially owns 5,286 shares of United Therapeutics common stock directly.
• The transaction was made pursuant to a Rule 10b5-1 trading plan, indicating it was pre-scheduled.

Sentiment

Score: 6

Explanation: The sale of a relatively small number of shares by a director, especially under a pre-arranged 10b5-1 plan, is generally considered a neutral event. It doesn't strongly indicate a positive or negative outlook for the company.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily based on new material non-public information.

Negatives

• A director selling shares, even under a 10b5-1 plan, reduces their direct ownership in the company.

Future Outlook

N/A

Industry Context

This is a routine insider transaction report and does not provide specific industry context or trends.

Related Party Transactions

• Nilda Mesa, a director of United Therapeutics Corp., sold 187 shares of common stock to the open market, which is considered a related party transaction due to her insider status.

Stakeholder Impact

• Minimal impact on shareholders due to the small number of shares involved in the transaction.
• No direct impact on employees, customers, suppliers, or creditors from this specific transaction.

Key Dates

Recommendation

The reported insider sale is a routine transaction under a 10b5-1 plan involving a small number of shares relative to the company's market capitalization. It does not provide sufficient new information to warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Director Sale, Stock Transaction, Nilda Mesa, 10b5-1 Plan